Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
13MAY

Mykor's £4m grows panels from mushrooms

3 min read
20:05UTC

Bristol's Mykor raised £4m on 27 May to grow building panels from mycelium, with £337m in orders signed before the first panel ships. Demand proven ahead of production, the opposite of most cleantech risk.

TechnologyDeveloping
Key takeaway

Mykor booked £337m in orders before shipping a single panel, inverting the usual cleantech risk.

Mykor, a Bristol company, raised £4m on Wednesday 27 May, led by the Clean Growth Fund with co-investors The FSE Group and Green Angel Ventures plus an Innovate UK grant, taking total funding to £7.5m 1. Mykor grows structural insulated panels from engineered mycelium, the root structure of fungi, and agricultural waste. The panels, branded MykoSIP, carry 60% less embodied carbon than conventional insulation and a Euroclass B fire rating, the European standard for limited combustibility. Co-founders Olivia Page and Valentina Dipietro are Forbes 30 Under 30 honourees, and the company employs 22 staff.

The number that separates Mykor from most cleantech is the order book: £337m in pre-production commercial agreements signed with UK and European contractors 2. That figure matters because it is signed before the first panel ships, which inverts the usual cleantech risk. Most materials startups burn capital proving a market exists; Mykor has booked demand and now needs to build supply. The £4m funds production capacity against contracts already in hand, not a hope that buyers will appear.

A Bristol firm with 22 staff is a different animal from a London AI raise, and that is the point. The regional, non-Golden-Triangle deeptech tier is alive, echoing earlier rounds outside the south-east such as Rivan's £25m for a synthetic-gas plant in Wiltshire and the regional life-sciences manufacturing sites the Life Sciences Innovative Manufacturing Fund backed in April . These companies raise from cleantech specialists and grant bodies, not the funds chasing the next billion-dollar AI label, which is exactly why the aggregate capital figures pass them by while the work goes on.

Deep Analysis

In plain English

Most building insulation, the material packed into walls to keep heat in, comes from mineral wool (rock or glass fibres) or plastic foam. Both require energy-intensive industrial processes to make, which creates carbon emissions before the building even opens. This is called 'embodied carbon'. Mykor grows its panels from mycelium, the root-like network of a fungus, combined with agricultural waste like straw or husks. The mycelium binds the waste material together into a rigid panel. Growing the panels uses far less energy than manufacturing conventional insulation, so the embodied carbon is roughly 60% lower. The fire rating matters because buildings have to pass fire safety tests; Mykor's panels have achieved a Euroclass B rating, which means they meet the standard required for most commercial and residential construction. The £337m in pre-production agreements means large building contractors have already committed to buy these panels once production scales up, before the first production line reaches full volume.

Deep Analysis
Root Causes

UK construction's embodied-carbon problem persists for two reasons operating at different speeds. In the short term, procurement departments at large contractors price on upfront material cost rather than whole-life carbon cost, because planning and building regulations do not yet require embodied-carbon reporting.

Mykor's pre-production agreements are an early signal that the 2025 Future Homes Standard consultation, which proposed mandatory whole-life carbon assessments, is already shifting contractor behaviour ahead of legal requirement.

In the medium term, the clean-build materials market lacks a domestic institutional anchor comparable to Longwall for deeptech. The Clean Growth Fund, which led Mykor's round, is the primary UK-domiciled cleantech early-stage vehicle at this cheque size. Innovate UK grant co-funding supplements equity but does not replace it. The result is a concentration of supply: if Clean Growth Fund's follow-on appetite changes, Mykor's next round has limited alternative domestic leads.

What could happen next?
  • Opportunity

    The £337m pre-production pipeline, if it converts at standard construction industry lead times of 2-4 years, would take Mykor from a £7.5m funded startup to a company with material revenue comparable to its total funding raise, without requiring additional equity.

  • Risk

    Installer-skills gaps for biogenic panel systems could delay conversion of the pre-production pipeline; the Ecovative precedent shows 4-6 year lags between signing and volume delivery for novel materials.

First Reported In

Update #6 · Orbital's $50m has no UK lead

Tech Funding News· 29 May 2026
Read original
Different Perspectives
Institute of Physics
Institute of Physics
The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.
Helsing
Helsing
The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.
British Business Bank
British Business Bank
The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.
Daphni
Daphni
The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.
EQT
EQT
EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.